OncoMatch/Clinical Trials/NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Is NCT06106945 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including AZD0305 and Elranatamab for multiple myeloma.
Treatment: AZD0305 · Elranatamab · Pomalidomide · Dexamethasone — This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Participants must have received at least 3 prior lines of treatment in module 1, or 1-3 prior lines in modules 2 and 3, with additional module-specific requirements related to prior lines of therapy
Cannot have received: anti-GPRC5D therapy
Participants who have previously received anti-GPRC5D
Cannot have received: MMAE-containing treatment
Participants who have previously received ... MMAE-containing treatment
Cannot have received: allogenic stem cell transplant
Participants who have previously received allogenic stem cell transplant
Lab requirements
Blood counts
Adequate bone marrow function per CSP module
Kidney function
Adequate renal function per CSP module
Liver function
Adequate hepatic function per CSP module
Adequate organ and bone marrow function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP as relevant to each module
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Duarte, California
- Research Site · Irvine, California
- Research Site · Atlanta, Georgia
- Research Site · Boston, Massachusetts
- Research Site · Ann Arbor, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06106945 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-GPRC5D therapy, MMAE-containing treatment, allogenic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages